Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms

Key facts

Sponsor

Massachusetts General Hospital

Principal Investigator

Hanny Al-Samkari, MD

Massachusetts General Hospital

Intervention

Blood Draw(procedure)

Enrollment

100 enrolled

Eligibility

18 years · All sexes

Timeline

2022 – 2026

Study locations (1)

• Massachusetts General Hospital, Boston, Massachusetts, United States

Collaborators

Agios Pharmaceuticals, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Disorder of glycolysis

Additional recruiting or active studies for the same condition.

• ACTIVE NOT RECRUITINGPHASE3NCT05144256
  A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension Period
  Agios Pharmaceuticals, Inc.
• ACTIVE NOT RECRUITINGPHASE3NCT05175105
  A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension Period
  Agios Pharmaceuticals, Inc.
• ACTIVE NOT RECRUITINGNCT03481738
  Pyruvate Kinase Deficiency Global Longitudinal Registry
  Agios Pharmaceuticals, Inc.

See all trials for Disorder of glycolysis →